Re-evaluating the balance of efficacy and safety with disease-modifying therapies

June 8, 2023

Recommend to a Colleague print

 

Includes data on early use of high-efficacy DMTs, risks of undertreatment of MS, safety issues and de-risking anti-CD20 therapy during long-term use.
16 slides

Download the slide deck

Recommend to a Colleague

Related Posts

• CLINICAL CASES IN MS – WORSENING SYMPTOMS PRIOR TO OCRELIZUMAB INFUSION
  September 27, 2023
• Ofatumumab – update on long-term efficacy, safety
  September 25, 2023
• ECTRIMS-ACTRIMS 2023 coverage
  September 20, 2023
• ECTRIMS-ACTRIMS 2023 survey
  September 20, 2023
• K-index a predictor of T2 lesions in CIS, RIS
  September 14, 2023

Go back to home page